Loading…
Nicotine lozenges and behavioural interventions may help smokeless tobacco users to quit
Cochrane Central Register of Controlled trials (CENTRAL); Medline; Embase; PsycINFO. Additional sources were also searched for early versions of the review: Web of Science, Dissertation Abstracts Online, Scopus, Healthstar, ERIC, National Technical Information Service database and Current Contents....
Saved in:
Published in: | Evidence-based dentistry 2015-12, Vol.16 (4), p.104-105 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 105 |
container_issue | 4 |
container_start_page | 104 |
container_title | Evidence-based dentistry |
container_volume | 16 |
creator | Hurst, Dominic |
description | Cochrane Central Register of Controlled trials (CENTRAL); Medline; Embase; PsycINFO. Additional sources were also searched for early versions of the review: Web of Science, Dissertation Abstracts Online, Scopus, Healthstar, ERIC, National Technical Information Service database and Current Contents.
Randomised controlled trials and pseudo-randomised controlled trials allocating smokeless tobacco (ST) users to an intervention or control, or to different interventions. Interventions could be pharmacological (ie nicotine replacement therapy (NRT), bupropion, varenicline) or behavioural, and could be directed at individual ST users or at groups of users.
Two authors independently extracted data about participants, interventions, outcomes and methodological quality. Any discrepancies in extracted data were resolved by consensus. Synthesis followed standard Cochrane methodology.
Thirty-four trials were included, 32 from the USA, one from Sweden and one from Sweden and Norway. Sixteen of the trials assessed pharmacological interventions and 19 assessed behavioural interventions (two studies did both). Varenicline increased ST abstinence rates (risk ratio 1.34, 95% confidence interval (CI) 1.08-1.68). Bupropion did not show a benefit of treatment. Neither nicotine patch nor nicotine gum increased abstinence. Nicotine lozenges did increase tobacco abstinence (RR 1.36, 95% CI 1.17-1.59). Behvaioural interventions resulted in a RR of 1.39 (95% CI 1.25-1.55) for those already motivated to quit and 1.37 (95% CI 1.23-1.53) for anyone.
Varenicline, nicotine lozenges and behavioural interventions may help ST users to quit. Confidence in results for nicotine lozenges is limited. Confidence in the size of effect from behavioural interventions is limited because the components of behavioural interventions that contribute to their impact are not clear. |
doi_str_mv | 10.1038/sj.ebd.6401129 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1750432682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3898623561</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1949-d7e6982b81a1b485fe50c1b194e81cea5a3f8b096bcac65c4e900d982904890d3</originalsourceid><addsrcrecordid>eNpdkL1PwzAQxS0EoqWwMiJLLCwp58R27BFVfEkVLCCxRbZzpS5J3MZJpfLXk4qyMN07vd-d7h4hlwymDDJ1G1dTtOVUcmAs1UdkzHguE8G5PN5rmSYAXI_IWYwrAMhzEKdklEqpQDA5Jh8v3oXON0ir8I3NJ0ZqmpJaXJqtD31rKuqbDtstNp0PTaS12dElVmsa6_CFFcZIu2CNc4H2Edt9Rze9787JycJUES8OdULeH-7fZk_J_PXxeXY3T9ZMc52UOUqtUquYYZYrsUABjtnBQ8UcGmGyhbKgpXXGSeE4aoBymNDAlYYym5Cb373rNmx6jF1R--iwqkyDoY8FywXwLJUqHdDrf-hq-LAZrhsorrXUQvOBujpQva2xLNatr027K_4yy34AdGtuqQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1749969594</pqid></control><display><type>article</type><title>Nicotine lozenges and behavioural interventions may help smokeless tobacco users to quit</title><source>Springer Link</source><creator>Hurst, Dominic</creator><creatorcontrib>Hurst, Dominic</creatorcontrib><description>Cochrane Central Register of Controlled trials (CENTRAL); Medline; Embase; PsycINFO. Additional sources were also searched for early versions of the review: Web of Science, Dissertation Abstracts Online, Scopus, Healthstar, ERIC, National Technical Information Service database and Current Contents.
Randomised controlled trials and pseudo-randomised controlled trials allocating smokeless tobacco (ST) users to an intervention or control, or to different interventions. Interventions could be pharmacological (ie nicotine replacement therapy (NRT), bupropion, varenicline) or behavioural, and could be directed at individual ST users or at groups of users.
Two authors independently extracted data about participants, interventions, outcomes and methodological quality. Any discrepancies in extracted data were resolved by consensus. Synthesis followed standard Cochrane methodology.
Thirty-four trials were included, 32 from the USA, one from Sweden and one from Sweden and Norway. Sixteen of the trials assessed pharmacological interventions and 19 assessed behavioural interventions (two studies did both). Varenicline increased ST abstinence rates (risk ratio 1.34, 95% confidence interval (CI) 1.08-1.68). Bupropion did not show a benefit of treatment. Neither nicotine patch nor nicotine gum increased abstinence. Nicotine lozenges did increase tobacco abstinence (RR 1.36, 95% CI 1.17-1.59). Behvaioural interventions resulted in a RR of 1.39 (95% CI 1.25-1.55) for those already motivated to quit and 1.37 (95% CI 1.23-1.53) for anyone.
Varenicline, nicotine lozenges and behavioural interventions may help ST users to quit. Confidence in results for nicotine lozenges is limited. Confidence in the size of effect from behavioural interventions is limited because the components of behavioural interventions that contribute to their impact are not clear.</description><identifier>ISSN: 1462-0049</identifier><identifier>EISSN: 1476-5446</identifier><identifier>DOI: 10.1038/sj.ebd.6401129</identifier><identifier>PMID: 26680516</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Behavior Therapy ; Chewing Gum ; Dentistry ; Evidence-Based Dentistry ; Humans ; Tobacco Use Cessation Products ; Tobacco Use Disorder - prevention & control ; Tobacco, Smokeless ; Varenicline - therapeutic use</subject><ispartof>Evidence-based dentistry, 2015-12, Vol.16 (4), p.104-105</ispartof><rights>Copyright Nature Publishing Group Dec 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26680516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hurst, Dominic</creatorcontrib><title>Nicotine lozenges and behavioural interventions may help smokeless tobacco users to quit</title><title>Evidence-based dentistry</title><addtitle>Evid Based Dent</addtitle><description>Cochrane Central Register of Controlled trials (CENTRAL); Medline; Embase; PsycINFO. Additional sources were also searched for early versions of the review: Web of Science, Dissertation Abstracts Online, Scopus, Healthstar, ERIC, National Technical Information Service database and Current Contents.
Randomised controlled trials and pseudo-randomised controlled trials allocating smokeless tobacco (ST) users to an intervention or control, or to different interventions. Interventions could be pharmacological (ie nicotine replacement therapy (NRT), bupropion, varenicline) or behavioural, and could be directed at individual ST users or at groups of users.
Two authors independently extracted data about participants, interventions, outcomes and methodological quality. Any discrepancies in extracted data were resolved by consensus. Synthesis followed standard Cochrane methodology.
Thirty-four trials were included, 32 from the USA, one from Sweden and one from Sweden and Norway. Sixteen of the trials assessed pharmacological interventions and 19 assessed behavioural interventions (two studies did both). Varenicline increased ST abstinence rates (risk ratio 1.34, 95% confidence interval (CI) 1.08-1.68). Bupropion did not show a benefit of treatment. Neither nicotine patch nor nicotine gum increased abstinence. Nicotine lozenges did increase tobacco abstinence (RR 1.36, 95% CI 1.17-1.59). Behvaioural interventions resulted in a RR of 1.39 (95% CI 1.25-1.55) for those already motivated to quit and 1.37 (95% CI 1.23-1.53) for anyone.
Varenicline, nicotine lozenges and behavioural interventions may help ST users to quit. Confidence in results for nicotine lozenges is limited. Confidence in the size of effect from behavioural interventions is limited because the components of behavioural interventions that contribute to their impact are not clear.</description><subject>Behavior Therapy</subject><subject>Chewing Gum</subject><subject>Dentistry</subject><subject>Evidence-Based Dentistry</subject><subject>Humans</subject><subject>Tobacco Use Cessation Products</subject><subject>Tobacco Use Disorder - prevention & control</subject><subject>Tobacco, Smokeless</subject><subject>Varenicline - therapeutic use</subject><issn>1462-0049</issn><issn>1476-5446</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpdkL1PwzAQxS0EoqWwMiJLLCwp58R27BFVfEkVLCCxRbZzpS5J3MZJpfLXk4qyMN07vd-d7h4hlwymDDJ1G1dTtOVUcmAs1UdkzHguE8G5PN5rmSYAXI_IWYwrAMhzEKdklEqpQDA5Jh8v3oXON0ir8I3NJ0ZqmpJaXJqtD31rKuqbDtstNp0PTaS12dElVmsa6_CFFcZIu2CNc4H2Edt9Rze9787JycJUES8OdULeH-7fZk_J_PXxeXY3T9ZMc52UOUqtUquYYZYrsUABjtnBQ8UcGmGyhbKgpXXGSeE4aoBymNDAlYYym5Cb373rNmx6jF1R--iwqkyDoY8FywXwLJUqHdDrf-hq-LAZrhsorrXUQvOBujpQva2xLNatr027K_4yy34AdGtuqQ</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Hurst, Dominic</creator><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201512</creationdate><title>Nicotine lozenges and behavioural interventions may help smokeless tobacco users to quit</title><author>Hurst, Dominic</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1949-d7e6982b81a1b485fe50c1b194e81cea5a3f8b096bcac65c4e900d982904890d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Behavior Therapy</topic><topic>Chewing Gum</topic><topic>Dentistry</topic><topic>Evidence-Based Dentistry</topic><topic>Humans</topic><topic>Tobacco Use Cessation Products</topic><topic>Tobacco Use Disorder - prevention & control</topic><topic>Tobacco, Smokeless</topic><topic>Varenicline - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hurst, Dominic</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Evidence-based dentistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hurst, Dominic</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nicotine lozenges and behavioural interventions may help smokeless tobacco users to quit</atitle><jtitle>Evidence-based dentistry</jtitle><addtitle>Evid Based Dent</addtitle><date>2015-12</date><risdate>2015</risdate><volume>16</volume><issue>4</issue><spage>104</spage><epage>105</epage><pages>104-105</pages><issn>1462-0049</issn><eissn>1476-5446</eissn><abstract>Cochrane Central Register of Controlled trials (CENTRAL); Medline; Embase; PsycINFO. Additional sources were also searched for early versions of the review: Web of Science, Dissertation Abstracts Online, Scopus, Healthstar, ERIC, National Technical Information Service database and Current Contents.
Randomised controlled trials and pseudo-randomised controlled trials allocating smokeless tobacco (ST) users to an intervention or control, or to different interventions. Interventions could be pharmacological (ie nicotine replacement therapy (NRT), bupropion, varenicline) or behavioural, and could be directed at individual ST users or at groups of users.
Two authors independently extracted data about participants, interventions, outcomes and methodological quality. Any discrepancies in extracted data were resolved by consensus. Synthesis followed standard Cochrane methodology.
Thirty-four trials were included, 32 from the USA, one from Sweden and one from Sweden and Norway. Sixteen of the trials assessed pharmacological interventions and 19 assessed behavioural interventions (two studies did both). Varenicline increased ST abstinence rates (risk ratio 1.34, 95% confidence interval (CI) 1.08-1.68). Bupropion did not show a benefit of treatment. Neither nicotine patch nor nicotine gum increased abstinence. Nicotine lozenges did increase tobacco abstinence (RR 1.36, 95% CI 1.17-1.59). Behvaioural interventions resulted in a RR of 1.39 (95% CI 1.25-1.55) for those already motivated to quit and 1.37 (95% CI 1.23-1.53) for anyone.
Varenicline, nicotine lozenges and behavioural interventions may help ST users to quit. Confidence in results for nicotine lozenges is limited. Confidence in the size of effect from behavioural interventions is limited because the components of behavioural interventions that contribute to their impact are not clear.</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>26680516</pmid><doi>10.1038/sj.ebd.6401129</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1462-0049 |
ispartof | Evidence-based dentistry, 2015-12, Vol.16 (4), p.104-105 |
issn | 1462-0049 1476-5446 |
language | eng |
recordid | cdi_proquest_miscellaneous_1750432682 |
source | Springer Link |
subjects | Behavior Therapy Chewing Gum Dentistry Evidence-Based Dentistry Humans Tobacco Use Cessation Products Tobacco Use Disorder - prevention & control Tobacco, Smokeless Varenicline - therapeutic use |
title | Nicotine lozenges and behavioural interventions may help smokeless tobacco users to quit |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A19%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nicotine%20lozenges%20and%20behavioural%20interventions%20may%20help%20smokeless%20tobacco%20users%20to%20quit&rft.jtitle=Evidence-based%20dentistry&rft.au=Hurst,%20Dominic&rft.date=2015-12&rft.volume=16&rft.issue=4&rft.spage=104&rft.epage=105&rft.pages=104-105&rft.issn=1462-0049&rft.eissn=1476-5446&rft_id=info:doi/10.1038/sj.ebd.6401129&rft_dat=%3Cproquest_pubme%3E3898623561%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p1949-d7e6982b81a1b485fe50c1b194e81cea5a3f8b096bcac65c4e900d982904890d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1749969594&rft_id=info:pmid/26680516&rfr_iscdi=true |